J. R. K. Savage

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

Pharmacy, Molecular Genetics, Pharmacotherapy +13

Factors influencing the infant gut microbiome at age 3-6 months: Findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART)

Joanne E. Sordillo, Yanjiao Zhou, Michael J. McGeachie et al. · Journal of Allergy and Clinical Immunology · 2016 · 156 citations · Full text

Life Sciences, Microbiology, Pediatrics +14

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two<i>F508del</i>alleles

Jennifer L. Taylor‐Cousar, Marcus Mall, Bonnie W. Ramsey et al. · ERJ Open Research · 2019 · 103 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

The metabolomics of asthma control: a promising link between genetics and disease

Michael J. McGeachie, Amber Dahlin, Weiliang Qiu et al. · Immunity Inflammation and Disease · 2015 · 95 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17